Free tool
FAERS Monitor: Steqeyma
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761338 or its brand name (Steqeyma, Ustekinumab-Stba). Reports on generic versions are filed under their own applications.
Reports
371
Serious
293
79% of reports
Hospitalization
78
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intentional product use issue49
- suspected off label use45
- crohn^s disease41
- off label use35
- drug dose omission by device34
- intentional dose omission28
- accidental exposure to product24
- exposure via skin contact24
- condition aggravated21
- needle issue21
- death20
- device malfunction19
- product dose omission issue18
- fatigue15
- inappropriate schedule of product administration15
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 144 |
| 2026 | 226 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,788 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| suspected off label useSignal | 45 | 570.4 | 433.1 | 24,768 |
| intentional dose omissionSignal | 28 | 55.7 | 39.0 | 1,451 |
| exposure via skin contactSignal | 24 | 52.6 | 35.7 | 1,163 |
| needle issueSignal | 21 | 40.9 | 27.0 | 779 |
| intentional product use issueSignal | 49 | 31.7 | 24.4 | 1,433 |
| drug dose omission by deviceSignal | 34 | 24.6 | 17.9 | 750 |
| device malfunctionSignal | 19 | 15.3 | 9.9 | 241 |
| accidental exposure to productSignal | 24 | 13.2 | 9.0 | 260 |
| inappropriate schedule of product administrationSignal | 15 | 4.7 | 2.9 | 41 |
| condition aggravatedSignal | 21 | 3.9 | 2.6 | 43 |
| product dose omission issueSignal | 18 | 3.5 | 2.2 | 30 |
| off label useSignal | 35 | 2.3 | 1.7 | 25 |
| death | 20 | 1.3 | 0.9 | 1 |
| fatigue | 15 | 1.1 | 0.7 | 0 |
| crohn^s disease | 41 | 0.0 | 0.0 | 2,270,300 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.